CAIXABANK MULTISALUD, FI

Enters the portfolio at 2.65% weight.

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Enters the portfolio at 1.82% weight.

Enters the portfolio at 1.35% weight.

Enters the portfolio at 1.21% weight.

Enters the portfolio at 1.16% weight.

Enters the portfolio at 0.97% weight.

Enters the portfolio at 0.92% weight.

Enters the portfolio at 0.54% weight.

Enters the portfolio at 0.29% weight.

Enters the portfolio at 0.12% weight.

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Goes from 4.79% to 8.61%.

Goes from 5.35% to 8.07%.

Goes from 1.73% to 3.14%.

Goes from 2.46% to 3.70%.

Goes from 4.66% to 5.77%.

Goes from 1.49% to 2.49%.

Goes from 3.99% to 4.86%.

Goes from 0.82% to 1.66%.

Goes from 0.11% to 0.89%.

Goes from 0.50% to 1.01%.

Goes from 3.33% to 3.75%.